WO2016059198A1 - Compounds - Google Patents
Compounds Download PDFInfo
- Publication number
- WO2016059198A1 WO2016059198A1 PCT/EP2015/073974 EP2015073974W WO2016059198A1 WO 2016059198 A1 WO2016059198 A1 WO 2016059198A1 EP 2015073974 W EP2015073974 W EP 2015073974W WO 2016059198 A1 WO2016059198 A1 WO 2016059198A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- compound
- formula
- alkyl
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to arsenic compounds, particularly arsenobetaine and arsenosugar analogues and derivatives and their use in therapy, particularly for the prevention and/or treatment of cancer.
- arsenobetaine or 2-trimethylarsoniumylacetate is the most abundant organoarsenic compound found in marine mammals.
- Arsenosugars are also found to be abundant in seaweed and in some marine foods.
- Most arsenic compounds are considered to be highly toxic to humans.
- compounds such as arsenobetaine and arsenosugars have been classed as relatively inert and nontoxic.
- arsenic compounds such as arsenobetaine and arsenosugars
- these have mainly focussed on determining their toxicity profiles. Some studies have also been carried out to determine their metabolic pathways in mammals, but no conclusive mechanisms have yet been identified. Furthermore, studies of arsenic compounds such as arsenobetaine or arsenosugar analogues and derivatives for any therapeutic indications have so far been limited.
- the present invention provides arsenic compounds, particularly arsenobetaine and arsenosugar analogues and derivatives and their use in therapy, more particularly for the prevention and/or treatment of cancer, and even more particularly for the prevention and/or treatment of breast, ovarian, uterine, endometrial, cervical, womb, testis, thyroid, osteosarcoma and/or prostate cancer, preferably breast cancer.
- a first aspect of the invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof
- R 1 , R 2 and R 3 are independently alkyl
- R 5 , R 6 , R 7 , R 8 and R 9 are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted heteroalkyi, optionally substituted alkenyl, optionally substituted cycloalkyi, optionally substituted heterocycloalkyi, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted carboxyalkyi and optionally substituted hydroxyalkyi;
- L is optionally substituted aryl
- X is absent, alkylene or -NHC(0)(CH 2 ) n -;
- n is 0 or an integer between 1 and 20;
- L' is alkyl
- R 10 and R 11 are independently optionally substituted heterocycloalkyi
- R 12 is -OR 13 ;
- R 13 is optionally substituted alkyl
- the compound of Formula (I) may be a compound of Formula (la):
- R 4 is selected from the group consisting of optionally substituted alkyl, optionally substituted heteroalkyi, optionally substituted alkenyl, optionally substituted cycloalkyi, optionally substituted heterocycloalkyi, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted carboxyalkyi, optionally substituted hydroxyalkyi, halo, -OR 5 , -COOR 6 , -CN, -NR 7 R 8 , -SR 9 , L-X-SR 9 , -L'-R 10 and -L'-R 11 -R 12 ; and
- R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , X, L, L' and n are as defined above for Formula (I).
- the compound of Formula (I) may be a compound of Formula (lb):
- R 4 0;
- R 1 , R 2 and R 3 are as defined above for Formula (I).
- R 1 , R 2 and R 3 may independently be Ci -2 o alkyl, preferably C- ⁇ .- ⁇ 2 alkyl, more preferably Ci -6 alkyl, and more preferably methyl, ethyl or propyl. Methyl is particularly preferred.
- the compound of Formula (I) may be a compound of Formula (lc):
- the compound of Formula (I) may be a compound of Formula (Id):
- R 19 , R 20 and R 21 may independently be selected from the group consisting of H, -OH, -OR 13 , -COOH, -S0 3 H, and -OS0 3 H; and
- R 13 is as defined above for Formula (I).
- the compound of Formula (I) may be a compound Formula (le):
- R 22 may be selected from the group consisting of H, -OH and -OR 13 ; and R 13 is as defined above for Formula (I).
- R 4 may be -SR 9 , wherein R 9 is optionally substituted alkyl.
- R may be -SR , wherein -SR is glutathionyl.
- R may be L-X-SR , wherein L is aryl, X is - NHC(0)(CH 2 ) n -, n is an integer between 1 and 6, and R 9 is optionally substituted heteroalkyl.
- R 4 may be N-(S-glutathionylacetyl)amino)aryl.
- R 4 may be 4-N-(S- glutathionylacetyl)amino)phenyl.
- L may be optionally substituted phenyl, preferably phenyl.
- X may be -NHC(0)(CH 2 ) n -, wherein n is an integer between 1 and 6, preferably between 1 and 3.
- L' may be C 1-6 alkyl, preferably C 1-3 alkyl and more preferably a methylene group.
- R 1 , R 2 and R 3 may each be C 1-6 alkyl
- R 1 , R 2 and R 3 may each be methyl, and R 4 may be optionally substituted alkyl or optionally substituted C 2-6 carboxyalkyl.
- R 1 , R 2 and R 3 may each be methyl, and R 4 may be optionally substituted alkyl having a terminal substituent selected from the group consisting of -COOH, -OH and -OSO 3 H.
- the compounds may be optionally substituted with one or more hydroxy (-OH) groups in addition to the terminal substituent.
- Preferred substituents include halo, alkoxy, oxo, -COOH, -NH 2 , N0 2 , - OH, -SO 3 H, -OSO 3 H and -CN, and more preferably -OH, -COOH, halo and -OSO 3 H.
- the compound of Formula (I) may be selected from:
- the compound of Formula (I) may be any organic compound having the same or chirality.
- the compound of Formula (I) may be any organic compound having the same or chirality.
- a second aspect of the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof of the first aspect of the invention, optionally together with a pharmaceutically acceptable excipient.
- a third aspect of the invention provides a compound or a pharmaceutically acceptable salt thereof of any of the first aspect of the invention or a pharmaceutical composition of the second aspect of the invention for use in therapy.
- a fourth aspect of the invention provides a compound or a pharmaceutically acceptable salt thereof of any of the first aspect of the invention or a pharmaceutical composition of the second aspect of the invention for use in preventing and/or treating cancer, particularly a hormone-induced cancer.
- the cancer is particularly selected from the group consisting of ovarian, uterine, endometrial, cervical, womb, testis, thyroid, osteosarcoma and prostate cancer, preferably breast cancer.
- a fifth aspect of the invention provides a method for preventing and/or treating cancer, particularly a hormone-induced cancer which comprises administering to a subject in need thereof an effective amount of a compound or a pharmaceutically acceptable salt thereof or a pharmaceutical composition as defined herein.
- the cancer is particularly selected from the group consisting of breast, ovarian, uterine, endometrial, cervical, womb, testis, thyroid, osteosarcoma and prostate cancer, preferably breast cancer.
- the compounds of the present invention are provided for the prevention and/or treatment of cancer.
- the compounds are provided for the prevention and/or treatment of hormone-induced cancers.
- the cancer is particularly selected from the group consisting of breast, ovarian, uterine, endometrial, cervical, womb, testis, thyroid, osteosarcoma and prostate cancer).
- the compounds of the present invention are provided for the prevention and/or treatment of breast cancer.
- prevention and/or treatment of cancer means any effect which mitigates damage, to any extent.
- treatment means any amelioration of a disorder, disease, syndrome, condition, pain or a combination of two or more thereof.
- prevention means to prevent the condition from occurring, lessening the severity of the condition or to prevent the patient from deteriorating or getting worse, for example by halting the progress of the disease without necessarily ameliorating the condition.
- an “effective amount” it is meant a “therapeutically effective amount”, namely an amount of compound sufficient, upon single dose or multiple dose administration, to cause a detectable decrease in disease severity, to prevent advancement of a disease or alleviate disease symptoms beyond that expected in the absence of treatment.
- Compounds of the invention are useful for treating or reducing the severity of symptoms of cancer, particularly a hormone induced cancer.
- the compounds are particularly useful for treating or reducing the severity of symptoms of breast, ovarian, uterine, endometrial, cervical, womb, testis, thyroid, osteosarcoma and prostate cancer, more particularly breast cancer.
- Compounds of the invention are also useful for administration to patients susceptible to, at risk of or suffering from cancer as set out above.
- Compounds useful for the prevention of cancer as set out above are not required to absolutely prevent occurrence of the disorder in all cases, but may prevent or delay onset of the disorder when administered to a patient susceptible to or at risk of the disorder.
- the compounds of the present invention are provided for the prevention and/or treatment of cancer in a subject in need thereof.
- the subject can be a human or an animal, particularly aquatic animals such as fish or domestic or farm animals such as dogs, cats, mice, rats, cattle, sheep, pigs and fowl.
- the subject is preferably a human.
- halogen or "halo” as used herein means fluorine, chlorine, bromine, iodine and the like.
- aliphatic refers to a straight or branched chain hydrocarbon which is completely saturated or contains one or more units of unsaturation.
- aliphatic may be alkyl, alkenyl or alkynyl, preferably having 1 to 12 carbon atoms, up to 6 carbon atoms or up to 4 carbon atoms.
- alkyl refers to a straight or branched chain alkyl group.
- an alkyl group as referred to herein is a C 1-2 o alkyl group. More preferably, an alkyl group as referred to herein is a lower alkyl having 1 to 6 carbon atoms. The alkyl group therefore has 1 , 2, 3, 4, 5 or 6 carbon atoms. Specifically, examples of "a lower (d.
- alkyl include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, 1 ,1-dimethylpropyl, 1 ,2-dimethylpropyl, 2,2-dimethylpropyl, 1 -ethylpropyl, n- hexyl, 1 -ethyl-2-methylpropyl, 1 ,1 ,2-trimethylpropyl, 1-ethylbutyl, 1-methylbutyl, 2- methylbutyl, 1 ,1-dimethylbutyl, 1 ,2-dimethylbutyl, 2,2-dimethylbutyl, 1 ,3-dimethylbutyl, 2,3- dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl and the like.
- heteroalkyl 1-ethyl
- alkoxy refers to an oxy group that is bonded to an alkyl group as defined herein.
- An alkoxy is preferably a "C1-12 alkoxy group", more preferably a "C1-10 alkoxy group”, even more preferably a "Ci -8 alkoxy group” and even more preferably a "C 1-6 alkoxy group”.
- cycloalkyl refers to a fully saturated hydrocarbon cyclic group.
- a cycloalkyl group is a C 3-6 cycloalkyl group.
- heterocycle refers to a saturated or partially unsaturated cyclic group having, in addition to carbon atoms, one or more heteroatoms selected from O, N and S.
- a heterocycle preferably has 3 to 7 ring atoms, and more preferably has 5 or 6 ring atoms.
- aryl refers to a monocyclic or bicyclic aromatic ring having 6 to 14 carbon atoms, preferably 6 to 10 carbon atoms.
- an aryl is phenyl.
- heteroaryl refers to a monocyclic or bicyclic aromatic ring system having 5 to 14 ring atoms, at least one ring atom being a heteroatom selected from O, N or S.
- a heteroaryl is a monocyclic or bicyclic aromatic ring system having 5 to 10 ring atoms, at least one ring atom being a heteroatom selected from O, N or S.
- a monocyclic heteroaryl is an aromatic ring system having 5 to 7 ring atoms, at least one ring atom being a heteroatom selected from O, N or S.
- a monocyclic heteroaryl is an aromatic ring system having 5 or 6 ring atoms, at least one ring atom being N.
- the term "optionally substituted” as used herein refers to a group that may be unsubstituted or substituted by one or more substituents.
- An aryl, heteroaryl or heterocycle group as referred to herein may be unsubstituted or may be substituted by one or more substituents independently selected from the group consisting of halo, aliphatic, heteroaliphatic, alkoxy, oxo, alkylamino (monoalkylamino or dialkylamino), -NH 2 , -N0 2 , -OH, -COOH, -SO 3 H, -CN, -OSO 3 H, hydroxyalkyl, alkylcarbonyloxy, alkoxycarbonyl, alkylcarbonyl, carboxyalkyl and alkylsulfonylamino.
- An aliphatic (including alkyl, alkenyl and cycloalkyl), heteroalkyl, carboxyalkyl, or hydroxyalkyl group as referred to herein may be unsubstituted or may independently be substituted with aryl, heteroaryl, heterocycle or with any one or more of the substituents listed above for aryl, heteroaryl or heterocycle groups.
- aralkyl and “heteroaralkyl” as used herein refers to an alkyl group as defined above substituted with an aryl or heteroaryl group as defined above.
- the alkyl component of an "aralkyl” or “heteroaralkyl” group may be substituted with any one or more of the substituents listed above for an aliphatic group and the aryl or heteroaryl component of an "aralkyl” or “heteroaralkyl” group may be substituted with any one or more of the substituents listed above for aryl, heteroaryl or heterocycle groups.
- aralkyl is benzyl.
- a prodrug is any compound that may be converted under physiological conditions or by solvolysis to any of the compounds of the invention or to a pharmaceutically acceptable salt of the compounds of the invention.
- a prodrug may be inactive when administered to a subject but is converted in vivo to an active compound of the invention.
- one or more asymmetric carbon atoms may be present.
- the invention is understood to include all isomeric forms (e.g. enantiomers and diastereoisomers) of the compounds as well as mixtures thereof, for example racemic mixtures.
- the compounds of the invention may be provided as the free compound or as a suitable salt or hydrate thereof.
- Salts should be those that are pharmaceutically acceptable and salts and hydrates can be prepared by conventional methods, such as contacting a compound of the invention with an acid or base whose counterpart ion does not interfere with the intended use of the compound.
- pharmaceutically acceptable salts include hydrohalogenates, inorganic acid salts, organic carboxylic acid salts, organic sulfonic acid salts, amino acid salt, quaternary ammonium salts, alkaline metal salts, alkaline earth metal salts and the like.
- the groups -OH, -COOH, -S0 3 H, -OSO 3 H and -NH 2 as referred to herein may be in the protonated or deprotonated form.
- -COOH as used herein also includes the deprotonated form, -COO " . This also applies to any other substituent mentioned herein which may exist in the protonated or deprotonated form.
- the compounds of the invention can be provided as a pharmaceutical composition.
- the pharmaceutical composition may additionally comprise a pharmaceutically acceptable excipient for example a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable diluent.
- a pharmaceutically acceptable excipient for example a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable diluent.
- Suitable carriers and/or diluents are well known in the art and include pharmaceutical grade starch, mannitol, lactose, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose (or other sugar), magnesium carbonate, gelatin oil, alcohol, detergents, emulsifiers or water (preferably sterile).
- a pharmaceutical composition may be provided in unit dosage form, will generally be provided in a sealed container and may be provided as part of a kit. Such a kit would normally (although not necessarily) include instructions for use. It may include a plurality of said unit dosage forms.
- a pharmaceutical composition may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route.
- Such compositions may be prepared by any method known in the art of pharmacy, for example by admixing the active ingredient with a carrier(s) or excipient(s) under sterile conditions.
- compositions adapted for oral administration may be presented as discrete units such as capsules or tablets; as powders or granules; as solutions, syrups or suspensions (in aqueous or non-aqueous liquids; or as edible foams or whips; or as emulsions).
- Suitable excipients for tablets or hard gelatine capsules include lactose, maize starch or derivatives thereof, stearic acid or salts thereof.
- Suitable excipients for use with soft gelatine capsules include for example vegetable oils, waxes, fats, semi-solid, or liquid polyols etc.
- excipients which may be used include for example water, polyols and sugars.
- compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
- the compositions are preferably applied as a topical ointment or cream.
- the active ingredient may be employed with either a paraffinic or a water-miscible ointment base.
- the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.
- Pharmaceutical compositions adapted for topical administration to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
- Pharmaceutical compositions adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.
- Pharmaceutical compositions adapted for rectal administration may be presented as suppositories or enemas.
- compositions adapted for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
- suitable compositions wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient.
- compositions adapted for administration by inhalation include fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulizers or insufflators.
- Pharmaceutical compositions adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
- compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solution which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation substantially isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- Excipients which may be used for injectable solutions include water, alcohols, polyols, glycerine and vegetable oils, for example.
- compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carried, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
- the pharmaceutical compositions may contain preserving agents, solubilising agents, stabilising agents, wetting agents, emulsifiers, sweeteners, colourants, odourants, salts, buffers, coating agents or antioxidants. They may also contain an adjuvant and/or therapeutically active agents in addition to the substance of the present invention.
- Dosages of the substance of the present invention can vary between wide limits, depending upon a variety of factors including the disease or disorder to be treated, the age, weight and condition of the individual to be treated, the route of administration etc. and a physician will ultimately determine appropriate dosages to be used.
- the dosage adopted for each route of administration when a compound of the invention is administered to adult humans is 0.001 to 500 mg/kg.
- Such a dosage may be given, for example, from 1 to 5 times daily by bolus infusion, infusion over several hours and/or repeated administration.
- compositions may be administered in conjunction with one or more other therapeutically active agents, especially those effective for treating cancers (i.e. a chemotherapeutic agent).
- a chemotherapeutic agent may be, for example, mitoxantrone, Vinca alkaloids, such as vincristine and vinblastine, anthracycline antibiotics such as daunorubicin and doxorubicin, alkylating agents such as chlorambucil and melphalan, taxanes such as paclitaxel, anti-folates such as methotrexate and tomudex, epipodophyllotoxins such as etoposide, camptothecins such as irinotecan and its active metabolite SN-38 and DNA methylation inhibitors.
- the other active compound(s) may be incorporated in the same composition as the compounds of the present invention or they may be administered alongside the compounds of the present invention, e.g. simultaneously or sequentially.
- the invention provides a kit of parts comprising a compound of the invention and another chemotherapeutic agent, optionally with instructions for use.
- FIG. 1 MDA-MB-231 primary tumor growth.
- Arsenobetaine Compound 2
- Group 3 versus the corresponding Vehicle Control Aqua ad injectabile (Group 1 ).
- Data are displayed as means ⁇ SEM.
- FIG. 2 MDA-MB-231 primary tumor volumes, measured in vivo on day 64.
- Arsenobetaine Compound 2
- Group 3 versus the corresponding Vehicle Control Aqua ad injectabile (Group 1 ).
- Data are displayed both as means + SEM (A) and as individual data points together with their corresponding median values (B).
- FIG. 3 MDA-MB-231 primary tumor volumes (mm 3 ).
- Compound 2 (arsenobetaine), administered at 1300 mg/kg (Group 3) versus the corresponding Vehicle Control Aqua ad injectabile (Group 1 ).
- Data are displayed both as means + SEM (A) and as individual data points together with their corresponding median values (B).
- FIG. 4 MDA-MB-231 primary tumor weight (g).
- Compound 2 arsenobetaine
- Group 3 versus the corresponding Vehicle Control Aqua ad injectabile (Group 1 ).
- Data are displayed both as means + SEM (A) and as individual data points together with their corresponding median values (B).
- MDA-MB 231 breast cancer cell line which is a model of ER-negative breast cancers was used.
- MDA-MB 231 cell line is particularly useful as it is highly aggressive both in vivo and in vitro.
- This study part consisted of experimental groups each containing 12 female BALB/c nude mice after randomization.
- 5x10 6 MDA-MB-231 tumor cells in 10 ⁇ PBS were implanted subcutaneously (s.c.) into the left flank of all female BALB/c nude mice.
- the tumor-bearing animals were randomized into groups according to tumor sizes.
- treatment with Vehicle and arsenobetaine was initiated.
- Vehicle (8ml/kg 200 ⁇ l/25g Aqua ad injectabile; Group 1 )
- compound 2 (arsenobetaine, 1300mg/kg) was administered 1x daily orally (p.o.) (see Table 1 ).
- Animal weights increased continuously until start of treatment on day 41 . After start of each of the three treatment cycles (days 41 -45, 48-52 and 55-59, respectively) animal weights of both groups started to decrease but recovered always after completion of each treatment cycle.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1707536.7A GB2546703A (en) | 2014-10-17 | 2015-10-16 | Compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1418491.5A GB201418491D0 (en) | 2014-10-17 | 2014-10-17 | Compounds |
GB1418491.5 | 2014-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016059198A1 true WO2016059198A1 (en) | 2016-04-21 |
Family
ID=52013185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2015/073974 WO2016059198A1 (en) | 2014-10-17 | 2015-10-16 | Compounds |
Country Status (2)
Country | Link |
---|---|
GB (2) | GB201418491D0 (en) |
WO (1) | WO2016059198A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006020048A2 (en) * | 2004-07-16 | 2006-02-23 | The Texas A & M University System | Compounds and methods for treatment of cancer |
-
2014
- 2014-10-17 GB GBGB1418491.5A patent/GB201418491D0/en not_active Ceased
-
2015
- 2015-10-16 WO PCT/EP2015/073974 patent/WO2016059198A1/en active Application Filing
- 2015-10-16 GB GB1707536.7A patent/GB2546703A/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006020048A2 (en) * | 2004-07-16 | 2006-02-23 | The Texas A & M University System | Compounds and methods for treatment of cancer |
Non-Patent Citations (3)
Title |
---|
KOSHIUKA K ET AL: "Novel therapeutic approach: Organic arsenical (melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo", BRITISH JOURNAL OF CANCER, vol. 82, no. 2, January 2000 (2000-01-01), pages 452 - 458, XP002751551, ISSN: 0007-0920 * |
SAKURAI TERUAKI ET AL: "Modulation of cell adhesion and viability of cultured murine bone marrow cells by arsenobetaine, a major organic arsenic compound in marine animals", BRITISH JOURNAL OF PHARMACOLOGY, vol. 132, no. 1, January 2001 (2001-01-01), pages 143 - 150, XP002752134, ISSN: 0007-1188 * |
VAN DER LUIT ARNOLD H ET AL: "A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells", MOLECULAR CANCER THERAPEUTICS, vol. 6, no. 8, August 2007 (2007-08-01), pages 2337 - 2345, XP002751549, ISSN: 1535-7163 * |
Also Published As
Publication number | Publication date |
---|---|
GB201707536D0 (en) | 2017-06-28 |
GB2546703A (en) | 2017-07-26 |
GB201418491D0 (en) | 2014-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2683355T3 (en) | Prodrugs of smokers and their use in the treatment of various diseases | |
ES2951127T3 (en) | SGLT2 inhibitors for the treatment of metabolic disorders in canine animals | |
KR101605151B1 (en) | Sigma ligands for the prevention or treatment of pain induced by chemotherapy | |
JP2019514962A (en) | Combination therapy for cancer treatment | |
KR101986272B1 (en) | Tricyclic compounds, compositions comprising them and uses thereof | |
TWI522357B (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
JP2015535247A5 (en) | ||
US20110071100A1 (en) | Sulfobetaines for cancer, obesity, macular degeneration, neurodegenerative diseases | |
RU2014135436A (en) | RTK INHIBITOR COMBINATION WITH ANTIESTROGEN AND ITS APPLICATION FOR TREATMENT OF CANCER | |
US20170056336A1 (en) | Co-targeting androgen receptor splice variants and mtor signaling pathway for the treatment of castration-resistant prostate cancer | |
JP2015502371A5 (en) | ||
US11071747B2 (en) | Use of NAD precursors for breast enhancement | |
CA2788150C (en) | Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent | |
CA3005751A1 (en) | Thieno-pyrimidine derivatives and uses thereof | |
SI3030554T1 (en) | Piperidine urea derivatives | |
RU2004133387A (en) | PHARMACEUTICAL PRODUCT WITH IMMEDIATE RELEASE | |
CA2914742A1 (en) | Handovers with co-operating cells configured to provide coordinated multi-point transmission/reception | |
NZ580867A (en) | Method of treating melanoma | |
CA2643400A1 (en) | Camptothecin derivatives and their uses | |
JP2013525290A5 (en) | ||
CN109475560B (en) | Treatment of neurological disorders | |
WO2016059198A1 (en) | Compounds | |
JP5973455B2 (en) | Therapeutic and preventive agents for demyelinating diseases | |
JP2010509389A (en) | Pyrrolo [1,2-a] imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents | |
US10507228B2 (en) | Methods and compositions related to KRAS inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15784942 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 201707536 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20151016 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15784942 Country of ref document: EP Kind code of ref document: A1 |